|June 7, 2017|
|Verastem to Present Long-Term Follow-Up Data from the DYNAMO™ Study at the 14th International Conference on Malignant Lymphoma|
Duvelisib Monotherapy Treatment Demonstrates 47% ORR in Patients with Double-Refractory Indolent Non-Hodgkin Lymphoma
88% of Patients had a Reduction in the Size of Target Lymph Nodes
Duvelisib Remains Well-Tolerated in Long-Term Follow Up
The long-term follow-up results from the study will be highlighted in an
oral presentation titled, “DYNAMO: A Phase 2 Study Demonstrating the
Clinical Activity of Duvelisib in Patients with Double-Refractory
Indolent Non-Hodgkin Lymphoma,” given by Pier Luigi Zinzani, MD, PhD,
“The data we are presenting at ICML help fill in the clinical picture for those patients who receive duvelisib over a longer period,” noted Dr. Zinzani. “Not only did duvelisib monotherapy continue to show robust and durable responses in double-refractory iNHL, but longer-term exposure to duvelisib did not reveal any unexpected safety findings. These results suggest duvelisib has favorable benefit-risk in double-refractory iNHL, and may provide an important new treatment option for a population in need of new targeted therapies.”
Patients enrolled in DYNAMO all had double-refractory iNHL and a median of 3 prior anticancer regimens. Of the 129 patients enrolled, 61 responded (1 complete response [CR], 60 partial responses [PR]), for an overall response rate (ORR) of 47%, as determined by an independent review committee. The ORR in each of the three disease subgroups included: 43% in follicular lymphoma (n=83); 68% in small lymphocytic lymphoma (n=28); and 33% in marginal zone lymphoma (n=18). Responses generally occurred shortly after the start of treatment (median 2 months). Notably, 88% of all patients treated with duvelisib had a reduction in the size of their target lymph nodes. Overall, median duration of response was 10 months, median progression-free survival was 9 months, and median overall survival was 27.8 months.
With additional follow-up (median 18 months), the safety profile of duvelisib monotherapy remains consistent with what has been previously reported in iNHL and other hematologic malignancies. The most common Grade ≥ 3 adverse events were hematologic in nature (neutropenia 30%, thrombocytopenia 15%, anemia 14%). Diarrhea was the most frequently reported nonhematologic adverse event (47%; 15% Grade ≥ 3). As expected in a heavily pretreated and refractory patient population, infections of all types and grades were observed (56%). Pneumonitis and colitis, events previously described with duvelisib, remained relatively uncommon (9% and 5%, respectively). Treatment discontinuations attributed to the most common adverse events were infrequent, suggesting that these events were generally manageable.
“The clinical activity and durability of responses observed in the
DYNAMO study seen across a range of highly-refractory disease subtypes,
together with the well-characterized and manageable safety profile,
highlight the potential of this drug in lymphoid malignancies,” said
Following conclusion of Dr. Zinzani's presentation, a copy of the presentation will be available here.
More About the Phase 2 DYNAMO™ Study
DYNAMO™ is a Phase 2, single-arm study, which evaluated the efficacy and safety of duvelisib 25 mg twice daily as monotherapy in 129 iNHL patients, including follicular lymphoma (n=83), small lymphocytic lymphoma (n=28), and marginal zone lymphoma (n=18) whose disease has progressed and are refractory to rituximab and to either chemotherapy or radioimmunotherapy. The primary endpoint of the study was ORR as assessed by an independent review committee.
About the Tumor Microenvironment
The tumor microenvironment encompasses multiple tumor and non-tumor cell populations and an extracellular matrix that support cancer cell survival. This includes immunosuppressive regulatory T-cells, myeloid-derived suppressor cells, tumor-associated macrophages, cancer-associated fibroblasts, and extracellular matrix proteins that can hamper the entry and therapeutic benefit of cytotoxic T-cells and anti-cancer drugs. In addition to targeting the proliferative and survival signaling of cancer cells, Verastem’s product candidates, including duvelisib and defactinib, also target the tumor microenvironment to potentially improve response to therapy.
Duvelisib is an investigational, dual inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma, two enzymes known to help support the growth and survival of malignant B-cells and T-cells. PI3K signaling may lead to the proliferation of malignant B-cells and is thought to play a role in the formation and maintenance of the supportive tumor microenvironment.1,2,3 Duvelisib is currently being evaluated in late- and mid-stage clinical trials, including DUO™, a randomized, Phase 3 monotherapy study in patients with relapsed or refractory CLL,4 and DYNAMO™, a single-arm, Phase 2 monotherapy study in patients with refractory iNHL that achieved its primary endpoint of ORR.5 Duvelisib is also being evaluated for the treatment of hematologic malignancies through investigator-sponsored studies, including T-cell lymphoma.6 Information about duvelisib clinical trials can be found on www.clinicaltrials.gov.
This press release includes forward-looking statements about
|You may automatically receive Verastem Inc financial information by e-mail. To choose your options for e-mail notification, please enter your e-mail address below and click Submit. On the next page you will be able to choose from the following options:|
To change your e-mail options at any time, re-enter your e-mail address and click Submit, then adjust your form entries.